Application and evaluation of denaturing HPLC for molecular genetic analysis in tuberous sclerosis

被引:52
作者
Jones, AC
Sampson, JR
Hoogendoorn, B
Cohen, D
Cheadle, JP
机构
[1] Cardiff Univ, Inst Med Genet, Cardiff CF14 4XN, S Glam, Wales
[2] Cardiff Univ, Div Psychol Med, Cardiff CF14 4XN, S Glam, Wales
[3] Univ Glamorgan, Sch Business Studies, Hlth Econ Unit, Pontypridd CF62 4XW, Rhondda, Wales
关键词
D O I
10.1007/s004390050040
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Tuberous sclerosis (TSC) is an autosomal dominant disorder characterised by the development of hamartomas in multiple tissues and organs. TSC exhibits locus heterogeneity with genes at 9q34 (TSC1) and 16p13.3 (TSC2) that have 21 and 41 coding exons, respectively. The mutational spectrum at both loci is wide and previous studies have shown that 60%-70% of cases are sporadic and represent new mutations. We have formatted denaturing high performance liquid chromatography (DHPLC) for rapid screening of all coding exons of TSC1 and TSC2. DHPLC analysis detected likely disease-causing mutations in 103 of 150 unrelated cases (68%), compared with 92/150 (61%) and 87/150 (58%) fdr single-strand conformation polymorphism analysis (SSCP) and conventional heteroduplex analysis (HA), respectively. Capital, consumable and labour costs were determined for each exon screening procedure. Estimated costs per patient sample depended on throughput, particularly for DHPLC, where a high proportion of costs are fixed, and were pound 257, pound 216 and pound 242 for DHPLC, SSCP and HA, respectively, assuming a throughput of 252 samples per year, or pound 354, pound 233 and pound 259, assuming a throughput of 126 samples per year. DHPLC had the advantages of increased sensitivity and reduced labour costs when compared with more traditional approaches to exon screening but, unless expensive DHPLC equipment is being efficiently utilised for a very high proportion of the time available, overall costs are slightly higher.
引用
收藏
页码:663 / 668
页数:6
相关论文
共 34 条
[1]   Mutations in the TSC1 gene account for a minority of patients with tuberous sclerosis [J].
Ali, JBM ;
Sepp, T ;
Ward, S ;
Green, AJ ;
Yates, JRW .
JOURNAL OF MEDICAL GENETICS, 1998, 35 (12) :969-972
[2]  
[Anonymous], 1991, ANN NY ACAD SCI
[3]   Germ-line mutational analysis of the TSC2 gene in 90 tuberous-sclerosis patients [J].
Au, KS ;
Rodriguez, JA ;
Finch, JL ;
Volcik, KA ;
Roach, ES ;
Delgado, MR ;
Rodriguez, E ;
Northrup, H .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (02) :286-294
[4]  
Beauchamp RL, 1998, HUM MUTAT, V12, P408, DOI 10.1002/(SICI)1098-1004(1998)12:6<408::AID-HUMU7>3.3.CO
[5]  
2-G
[6]  
Bénit P, 1999, HUM MUTAT, V14, P428, DOI 10.1002/(SICI)1098-1004(199911)14:5<428::AID-HUMU9>3.0.CO
[7]  
2-5
[8]   9Q34 LOSS OF HETEROZYGOSITY IN A TUBEROUS SCLEROSIS ASTROCYTOMA SUGGESTS A GROWTH SUPPRESSOR-LIKE ACTIVITY ALSO FOR THE TSC1 GENE [J].
CARBONARA, C ;
LONGA, L ;
GROSSO, E ;
BORRONE, C ;
GARRE, MG ;
BRISIGOTTI, M ;
MIGONE, N .
HUMAN MOLECULAR GENETICS, 1994, 3 (10) :1829-1832
[9]   Comprehensive mutation analysis of TSC1 using two-dimensional DNA electrophoresis with DGGE [J].
Dabora, SL ;
Sigalas, I ;
Hall, F ;
Eng, C ;
Vijg, J ;
Kwiatkowski, DJ .
ANNALS OF HUMAN GENETICS, 1998, 62 :491-504
[10]   The role of economic evaluation in the pricing and reimbursement of medicines [J].
Drummond, M ;
Jonsson, B ;
Rutten, F .
HEALTH POLICY, 1997, 40 (03) :199-215